New England Journal of Medicine Ahead of Print Articles

Scrofuloderma remains a distinct clinical presentation of cutaneous tuberculosis that continues to challenge dermatologists and infectious disease specialists, according to recent medical literature published in the New England Journal of Medicine on August 29, 2026. This rare form of skin infection typically develops through the direct extension of an underlying tuberculous focus, such as affected lymph nodes, bones, or joints, breaking through the dermal layers to form characteristic ulcers and sinuses.

Clinical Presentation and Diagnostic Challenges

Patients presenting with scrofuloderma frequently exhibit firm, painless subcutaneous nodules that progressively soften, ulcerate, and discharge caseous material. According to clinical reports in the New England Journal of Medicine, these lesions most commonly manifest in the cervical region, axillae, and groin where superficial lymph nodes reside. Because the clinical appearance can mimic other chronic inflammatory skin conditions or deep fungal infections, clinicians rely on biopsy, mycobacterial culture, and molecular testing to confirm the diagnosis.

Treatment Protocols and Management Standards

Management of scrofuloderma requires prolonged multidrug anti-tubercular chemotherapy aligned with standard guidelines for extrapulmonary tuberculosis. Medical specialists emphasize adherence to the complete therapeutic regimen to prevent treatment failure and the development of drug-resistant strains. Surgical intervention is generally reserved for debriding necrotic tissue or managing persistent scarring once active mycobacterial replication has been controlled by pharmacological agents.